WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: Belatacept ISE - CMAP, Study design incorporates Study duration, Blood pressure includes Diastolic pressure, Delayed graft function is associated with Acute Rejection risk, Calcineurin inhibitors include CsA, Dialysis treatment can occur Post-transplantation, Transplant recipients fit into Enrollment criteria, belatacept is used for Organ rejection, GFR is used to assess Chronic Kidney Disease, Framingham risk score incorporates Total cholesterol, Transplant donors are characterized by Donor condition, Immunosuppressive regimen includes Mycophenolate Mofetil (MMF), Efficacy endpoint includes Chronic Allograft Nephropathy (CAN), Framingham risk score incorporates Gender, Cardiovascular death includes Myocardial infarction, Serum Creatinine (SCr) can be thresholded at 1.5 mg/dL, Standard criteria are associated with Age, Calcineurin inhibitors are associated with Renal impairment, Chronic rejection impacts Graft survival, Transplant donors are characterized by Baseline biopsy vasculopathy, Transplant donors can be Deceased